Literature DB >> 17599852

Once-daily insulin glargine versus 6-hour sliding scale regular insulin for control of hyperglycemia after a bariatric surgical procedure: a randomized clinical trial.

Swati Datta1, Arshia Qaadir, Griselda Villanueva, David Baldwin.   

Abstract

OBJECTIVE: To determine whether once-daily insulin glargine could provide better glycemic control after an abdominal surgical procedure than the traditional use of sliding scale regular insulin (SSRI).
METHODS: Because 20% to 30% of patients undergoing gastric bypass have a history of overt diabetes and another 5% to 10% are estimated to have impaired glucose tolerance, we chose to study these patients. We treated 81 patients with postoperative blood glucose levels of more than 144 mg/dL after a Roux-en-Y gastric bypass surgical procedure. They were randomized to receive either SSRI or insulin glargine either directly or after initial intravenous insulin infusion in the intensive care unit (ICU).
RESULTS: Overall, the mean blood glucose level after SSRI therapy was 154 +/- 33 mg/dL, and the mean blood glucose value after insulin glargine treatment was 134 +/- 30 mg/dL (P<0.01). The mean blood glucose level for patients first treated with intravenous insulin infusion in the ICU was 125 mg/dL, in comparison with 145 mg/dL in the non-ICU patients whose treatment began directly with 0.3 U/kg of insulin glargine. Of 926 blood glucose measurements, only 3 were less than 60 mg/dL.
CONCLUSION: In this study, control of postoperative hyperglycemia was significantly better with use of insulin glargine in comparison with SSRI therapy, and hypoglycemia was very infrequent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17599852     DOI: 10.4158/EP.13.3.225

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  8 in total

Review 1.  Randomized controlled trials in bariatric surgery.

Authors:  Chien-Pin Chan; Bing-Yen Wang; Ching-Yuan Cheng; Ching-Hsiung Lin; Ming-Chia Hsieh; Jun-Jiun Tsou; Wei-Jei Lee
Journal:  Obes Surg       Date:  2013-01       Impact factor: 4.129

Review 2.  Perioperative Glycemic Management of Patients Undergoing Bariatric Surgery.

Authors:  David Rometo; Mary Korytkowski
Journal:  Curr Diab Rep       Date:  2016-04       Impact factor: 4.810

Review 3.  Transitioning safely from intravenous to subcutaneous insulin.

Authors:  Kathryn Evans Kreider; Lillian F Lien
Journal:  Curr Diab Rep       Date:  2015-05       Impact factor: 4.810

4.  Can a protocol for glycaemic control improve type 2 diabetes outcomes after gastric bypass?

Authors:  Wiebke K Fenske; Dimitri J Pournaras; Erlend T Aasheim; Alexander D Miras; Nicola Scopinaro; Samantha Scholtz; Carel W le Roux
Journal:  Obes Surg       Date:  2012-01       Impact factor: 4.129

5.  Comparison of Glycemic Control between Continuous Regular Insulin Infusion and Single-dose Subcutaneous Insulin Glargine Injection in Medical Critically Ill Patients.

Authors:  Rungsun Bhurayanontachai; Tharittamon Rattanaprapat; Chanon Kongkamol
Journal:  Indian J Crit Care Med       Date:  2018-03

6.  Sliding scale insulin for non-critically ill hospitalised adults with diabetes mellitus.

Authors:  Luis Enrique Colunga-Lozano; Franscisco Javier Gonzalez Torres; Netzahualpilli Delgado-Figueroa; Daniel A Gonzalez-Padilla; Adrian V Hernandez; Yuani Roman; Carlos A Cuello-García
Journal:  Cochrane Database Syst Rev       Date:  2018-11-29

7.  Management of diabetes by a healthcare team in a cardiology unit: a randomized controlled trial.

Authors:  Maria Antonieta P de Moraes; Juliane Rodrigues; Mariana Cremonesi; Carisi Polanczyk; Beatriz D Schaan
Journal:  Clinics (Sao Paulo)       Date:  2013-11       Impact factor: 2.365

8.  Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study.

Authors:  Nader D Nader; Hadi Hamishehkar; Abdolreza Naghizadeh; Kamran Shadvar; Afshin Iranpour; Sarvin Sanaie; Francis Chang; Ata Mahmoodpoor
Journal:  Diabetes Metab Syndr Obes       Date:  2020-03-10       Impact factor: 3.168

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.